Cancer cells may develop drug resistance by suppressing expression of the gene MED12, reports an international group of researchers (Huang S et al. Cell. 2012;151:937-950).
The researchers identified MED12 when looking for genes that, when suppressed, confer resistance to the targeted therapy crizotinib in non–small cell lung cancer cells. They then found that MED12 inhibition resulted in resistance not only to crizotinib, but also to other targeted drugs and chemotherapy used to treat colon cancer, melanoma, and liver cancer. Previous research has revealed mutations in MED12 in various types of cancer cells.
Hampton T. Cancer Drug Resistance. JAMA. 2013;309(1):20. doi:10.1001/jama.2012.173440